Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Deals With The DOJ

Executive Summary

A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.

Advertisement

Related Content

Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
Off-Label Convictions Of Device Execs Could Impact Pharma Sales Reps
Tarceva Off-Label Marketing Caused 'Earlier' Death, DOJ Alleged
Pfizer Protonix Settlement May Deter Price Bundling
Does Former Warner Chilcott Exec’s Arrest Portend More Prosecutions?
AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged
Teva False Claims Settlement Stems From Kickbacks To Single Doctor
Government Briefs: White House Moves On Patent Reform, DOJ Settles Endo Off-Label Complaints
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
The Era Of Billion Dollar Pharma Settlements

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel